Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration Save Sight Registries Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration Read More »
Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration Save Sight Registries Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration Read More »
Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration Save Sight Registries Two year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration Read More »
Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Save Sight Registries Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Read More »
Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD Save Sight Registries Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD Read More »
Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study Save Sight Registries Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study Read More »
Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Save Sight Registries Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Read More »
Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration Save Sight Registries Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration Read More »
Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Save Sight Registries Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Read More »
Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration Save Sight Registries Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration Read More »
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab Save Sight Registries Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab Read More »
Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Save Sight Registries Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Read More »